US-based contract research organisation (CRO) MDS Pharma Services can now offer clients a centralised, integrated system for managing, analysing, reporting and reviewing clinical research data, following its adoption of drug development technology from SAS, the leading supplier of business intelligence and analytical software and services.

The SAS Drug Development tool is being implemented across the range of MDS Pharma businesses, from preclinical to Phase IV, as a means of integrating workflows worldwide. It will also expedite the conversion of datasets into the format established for electronic regulatory submissions by the Clinical Data Interchange Standards Consortium (CDISC) for electronic regulatory submissions.

The CDISC is a US-based body set up to develop and support global, platform-independent data standards that enable interoperability of information systems to improve medical research and related areas of healthcare.

The SAS Drug Development system will allow MDS Pharma’s medium to large pharmaceutical clients to combine historical clinical trial data from a variety of sources and studies, convert it into a common format and analyse it to identify patient safety issues or new demographic groups with commercial potential, the CRO noted. Biotechnology clients will be able to integrate all available trial datasets and convert them into a unified data package for due diligence, subsequent licensing or joint venture opportunities.

“This powerful tool will significantly improve our internal operational efficiency and enhance our ability to provide quality, on-time service to clients at all phases of their drug development process,” said MDS Pharma Services president David Spaight. “It allows clients to view their study data even as it is being updated, serves as a secure repository of legacy clinical trial data, and can convert that data into standard CDISC format for electronic submission to regulators as part of a New Drug Application.”